Your browser doesn't support javascript.
loading
Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysis.
Fancellu, A; Houssami, N; Sanna, V; Porcu, A; Ninniri, C; Marinovich, M L.
Afiliação
  • Fancellu A; Department of Medical, Surgical and Experimental Sciences, Unit of General Surgery 2, Clinica Chirurgica, University of Sassari, Sassari, Italy.
  • Houssami N; Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • Sanna V; The Daffodil Centre, the University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.
  • Porcu A; Azienda Ospedaliero-Universitaria di Sassari, Unit of Medical Oncology, Sassari, Italy.
  • Ninniri C; Department of Medical, Surgical and Experimental Sciences, Unit of General Surgery 2, Clinica Chirurgica, University of Sassari, Sassari, Italy.
  • Marinovich ML; Department of Medical, Surgical and Experimental Sciences, Unit of General Surgery 2, Clinica Chirurgica, University of Sassari, Sassari, Italy.
Br J Surg ; 108(7): 760-768, 2021 07 23.
Article em En | MEDLINE | ID: mdl-34057990
ABSTRACT

BACKGROUND:

In patients with triple-negative breast cancer (TNBC), oncological and survival outcomes based on locoregional treatment are poorly understood. In particular, the safety of breast-conserving surgery (BCS) for TNBC has been questioned.

METHODS:

A meta-analysis was performed to evaluate locoregional recurrence (LRR), distant metastasis (DM), and overall survival (OS) rates in patients with TNBC who had breast-conserving surgery versus mastectomy. Estimates were pooled in random-effects analysis. The effect of study-level co-variables was assessed by univariable metaregression.

RESULTS:

Fourteen studies, including 19 819 patients operated for TNBC met the inclusion criteria; 9828 patients (49.6 per cent) underwent BCS and 9991 (50.4 per cent) had a mastectomy. Patients with smaller tumours were more likely to be selected for BCS (pooled odds ratio (OR) for T1 tumours 1.95, 95 per cent c.i. 1.64 to 2.32; P < 0.001). The pooled OR for LRR was 0.64 (0.48 to 0.85; P = 0.002), indicating a statistically significantly lower odds of LRR among women who had BCS relative to mastectomy. The pooled OR for DM was 0.70 (0.53 to 0.94; P = 0.02), indicating a lower odds of DM among women who had BCS; however, this difference diminished with increasing study-level age and follow-up time. A pooled hazard ratio of 0.78 (0.69 to 0.89; P < 0.001) showed a significantly lower hazard for all-cause mortality among women undergoing BCS versus mastectomy.

CONCLUSION:

These results should be interpreted cautiously owing to likely differences in selection for BCS or mastectomy in the included studies. Patients with TNBC selected for BCS do not, however, have a worse prognosis than those treated with mastectomy, and breast conservation can be offered when feasible clinically.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mastectomia Segmentar / Neoplasias de Mama Triplo Negativas / Estadiamento de Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mastectomia Segmentar / Neoplasias de Mama Triplo Negativas / Estadiamento de Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article